Citicoline (CDP-choline)
Also called: CDP-choline, cytidine diphosphocholine, cytidine 5'-diphosphocholine, cytidinediphosphocholine
CDP-choline (cytidine 5'-diphosphocholine) is a compound the body makes as a precursor for phosphatidylcholine, a cell-membrane component; when the same substance is given as a drug it can be called citicoline. It is also sold as a dietary supplement.
- Category
- Other
- Forms
- Citicoline (CDP-choline); trials gave it orally, intravenously or both
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-30
Class 1 Well studied in people. A 2020 Cochrane review identified 10 RCTs (4,281 people with acute ischemic stroke) of citicoline versus placebo or standard care, pooling up to 8 per outcome; citicoline was given orally, intravenously or both, and the abstract does not give an oral-only count. [1]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CHeart and blood vessels1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Memory and behavior in older people with chronic cerebral disorders | B | A 2005 Cochrane review of 14 double-blind placebo-controlled RCTs (most lasting 3 months or less; one 12 months) found some evidence of benefit on memory and behavior but none on attention. [2] |
| Cognitive status in mild cognitive impairment, Alzheimer's disease or post-stroke dementia | C | A 2023 meta-analysis of 6 studies found improved cognitive status with citicoline, but the overall quality of the studies was poor, with significant risk of bias favoring the intervention. [3] |
| Recovery after acute ischemic stroke | C | A 2020 Cochrane review (10 RCTs, 4,281 participants, all at high risk of bias) found little to no difference from controls in death, disability, functional recovery or neurological function (low-certainty evidence). [1] |
Main constituents: CDP-choline (cytidine 5'-diphosphocholine), a precursor essential for the synthesis of phosphatidylcholine [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Stroke trials gave 500 mg to 2,000 mg per day, orally, intravenously or both. [1]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- The 2020 Cochrane stroke review found adverse events poorly reported, states harms may have been underestimated, and concludes the safety profile of citicoline remains unknown; serious cardiovascular adverse events did not clearly differ from placebo (3 trials). [1]
- In the 2005 Cochrane review of older people with chronic cerebral disorders, the drug was well tolerated. [2]
Regulatory status
- EU: Commission Implementing Decision 2014/423/EU of 1 July 2014 authorized placing citicoline on the market as a novel food ingredient under Regulation (EC) No 258/97. [5]
- Drug use: the 2005 Cochrane review states CDP-choline is a frequently prescribed drug for cognitive impairment in several European countries. [2]
- US: no NDI notification naming citicoline or CDP-choline was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). [7]
- US: FDA's GRAS Notice Inventory returned no notice for citicoline (searched 2026-10-29). [6]
- US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [8]
- A 2020 systematic review states citicoline is widely available as a dietary supplement. [4]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- CDP-choline (cytidine 5'-diphosphocholine), an endogenous precursor of phosphatidylcholine; called citicoline when given as a drug Nucleotides (cytidine diphosphate ester of choline; phosphatidylcholine precursor) [P5]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming citicoline or CDP-choline was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P1]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P4]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606), 2026-10-29. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2005;(2):CD000269 (PMID 15846601), 2005-04-18. pubmed.ncbi.nlm.nih.gov
Sources
- Martí-Carvajal AJ, et al. Citicoline for treating people with acute ischemic stroke. Cochrane Database Syst Rev 2020;8:CD013066 (PMID 32860632), 2020-08-29. pubmed.ncbi.nlm.nih.gov
- Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2005;(2):CD000269 (PMID 15846601), 2005-04-18. pubmed.ncbi.nlm.nih.gov
- Bonvicini M, et al. Is citicoline effective in preventing and slowing down dementia? A systematic review and a meta-analysis. Nutrients 2023;15(2):386 (PMID 36678257), 2023-01-12. pubmed.ncbi.nlm.nih.gov
- Jasielski P, et al. Application of citicoline in neurological disorders: a systematic review. Nutrients 2020;12(10):3113 (PMID 33053828), 2020-10-12. pubmed.ncbi.nlm.nih.gov
- EUR-Lex. 2014/423/EU: Commission Implementing Decision of 1 July 2014 authorising the placing on the market of citicoline as a novel food ingredient under Regulation (EC) No 258/97 (notified under document C(2014) 4252), 2014-07-01. eur-lex.europa.eu
- U.S. FDA. GRAS Notice Inventory: search results for 'citicoline' (0 records; retrieved 2026-10-29), 2026-10-29. hfpappexternal.fda.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in this category: Alpha-lipoic acid · Bee pollen · Beetroot juice (dietary nitrate) · Berberine · Beta-glucan (oat and barley) · Betaine (trimethylglycine) · Bromelain · Caffeine · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.